相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
Zeeshan Butt et al.
CANCER (2013)
Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
Eitan Amir et al.
EUROPEAN JOURNAL OF CANCER (2012)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Jennifer L. Beaumont et al.
ONCOLOGIST (2011)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes
David Cella
CANCER TREATMENT REVIEWS (2009)
Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib
Peter C. Trask et al.
ACTA ONCOLOGICA (2008)
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
Kiran Gupta et al.
CANCER TREATMENT REVIEWS (2008)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Patient-reported outcomes in phase II cancer clinical trials: Lessons learned and future directions
Lynne I. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Olivier Rixe et al.
LANCET ONCOLOGY (2007)
Development and validation of a scale to measure disease-related symptoms of kidney cancer
David Cella et al.
VALUE IN HEALTH (2007)
Symptom burden among patients with Renal Cell Carcinoma (RCC): content for a symptom index
Gale Harding et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Effects of sorafenib on symptoms and quality of life - Results from a large randomized placebo-controlled study in renal cancer
Ronald Bukowski et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
